Sponsor content
847 result(s) found, displaying 291 to 300
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ISOCIPRALINE isoprenaline hydrochloride 1.0 mg/5 mL injection solution ampoule.
-
Australian public assessment report (AusPar)AusPAR for Filpegla (pegfilgrastim) for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia.
-
Australian public assessment report (AusPar)Ardalicip / Ciptunec (adalimumab) for the treatment of arthritis, crohn's disease, ulcerative colitis, psoriasis, uveitis and acne inversa.
-
Prescription medicine registrationActive ingredients: Methotrexate.
-
Australian public assessment report (AusPar)Trastucip and Tuzucip (trastuzumab) for the treatment of breast cancer and gastric cancer
-
Prescription medicine registrationActive ingredients: Cinacalcet hydrochloride.
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/01/2023
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/01/2023
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/01/2023
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., 29/01/2023